wild 9 Last month, Parliament approved $7,000 worth of new Tax-Free Savings Account (TFSA) contribution room for all eligible contributors in 2025. The newly added room takes the absolute maximum amount of available TFSA room from $95,000 to $102,000 — assuming that you were 18 or older in 2009. If you turned 18 in 2010 or later, then your cumulative amounts are less than those just cited. Your exact contribution room depends on how much you accumulated in the years in which you were eligible to open an account as well as the amounts you’ve already accumulated. One way or another, you’ll have some TFSA contribution room next year, whether that’s the year’s $7,000 or $102,000 accumulated over a lifetime. In this article, I will explore how you can potentially double your TFSA in value over seven short years — taking undue risks when seeking superior returns. Compound at 10% per year over seven years By simply compounding your TFSA wealth at 10% per year for seven years — more precisely 7.2 years — you can double your money. This is a return that is achievable with a broad market index fund assuming only moderately favourable circumstances. This might seem remarkable, but you need to remember that investment returns are compounded, not added. That means that you multiply the returns by one another instead of adding them up. The result is exponential growth that adds up surprisingly quickly. In the table below, you can see how compounding at 10% per year leads to an investment roughly doubling in seven years. As you can see, by the end of year eight, the amount has more than doubled. And thanks to “the Rule of 72,” we know that 7.2 years is the amount of time needed for the amount to double. Investments that can actually make this happen Now, as we’ve seen, the Rule of 72 dictates that it takes 7.2 years for an investment to double at a 10% annual rate of return. The next logical question is which types of investments can make that happen in reality. And the answer is broad market index funds. Nothing is ever a sure thing, but Canadian index funds usually return close to 10% per year, and they have enough diversification to make it plausible that the returns will continue in the long term. Consider ( ), for example. It’s a Canadian made up of 220 large-cap Canadian stocks. This is a significant amount of diversification. And, because the stocks in XIC are spread across different sectors, they are not too strongly correlated with one another. So, the prospect of high returns here going forward is very real. What does XIC have going for it apart from its diversification? First, it has a very low 0.05% management fee and a 0.06% management expense ratio (MER). These low fees mean that you don’t lose too much of your money to fund managers. Second, it is highly liquid, which means tight bid-ask spreads and little money lost to market makers. Third and finally, it is a , meaning no dividend withholding taxes and greater take-home returns than with foreign funds. It all adds up to a pretty compelling fund. And, costing just $40.82, you can easily afford to buy it in a no-commission account today.None

Peeling Back The Layers: Exploring Essential Props Realty Through Analyst InsightsYoung Star B335 Offers A Natural Laboratory for Astrochemistry

2027: Group wants FIRS boss to contest Oyo guber election

Croatia’s incumbent president wins most votes at polls but still faces runoff

MediToldlab, "Somono Toothpaste, a cold tooth Relieves Symptoms, Proven Through Human Application Tests"Young Boys players pay tribute to teammate Meschack Elia in Champions League game after his son died

Unlike scores of people who scrambled for the blockbuster drugs Ozempic and Wegovy to lose weight in recent years, Danielle Griffin had no trouble getting them. The 38-year-old information technology worker from New Mexico had a prescription. Her pharmacy had the drugs in stock. And her health insurance covered all but US$25 to US$50 of the monthly cost. For Griffin, the hardest part of using the new drugs wasn’t access. It was finding out that the much-hyped medications didn’t really work for her. “I have been on Wegovy for a year and a half and have only lost 13 pounds,” said Griffin, who watches her diet, drinks plenty of water and exercises regularly. “I’ve done everything right with no success. It’s discouraging.” In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15 per cent to 22 per cent of their body weight — up to 50 pounds or more in many cases. But roughly 10 per cent to 15 per cent of patients in those trials were “nonresponders” who lost less than five per cent of their body weight. Now that millions of people have used the drugs, several obesity experts told The Associated Press that perhaps 20 per cent of patients — as many as one in five — may not respond well to the medications. It's a little-known consequence of the obesity drug boom, according to doctors who caution eager patients not to expect one-size-fits-all results “It's all about explaining that different people have different responses,” said Dr. Fatima Cody Stanford, an obesity expert at Massachusetts General Hospital The drugs are known as GLP-1 receptor agonists because they mimic a hormone in the body known as glucagon-like peptide 1. Genetics, hormones and variability in how the brain regulates energy can all influence weight — and a person's response to the drugs, Stanford said. Medical conditions such as sleep apnea can prevent weight loss, as can certain common medications, such as antidepressants, steroids and contraceptives. “This is a disease that stems from the brain,” said Stanford. “The dysfunction may not be the same” from patient to patient. Despite such cautions, patients are often upset when they start getting the weekly injections but the numbers on the scale barely budge. “It can be devastating,” said Dr. Katherine Saunders, an obesity expert at Weill Cornell Medicine and co-founder of the obesity treatment company FlyteHealth. “With such high expectations, there’s so much room for disappointment.” That was the case for Griffin, who has battled obesity since childhood and hoped to shed 70 pounds using Wegovy. The drug helped reduce her appetite and lowered her risk of diabetes, but she saw little change in weight. “It’s an emotional roller coaster,” she said. “You want it to work like it does for everybody else.” The medications are typically prescribed along with eating behavior and lifestyle changes. It’s usually clear within weeks whether someone will respond to the drugs, said Dr. Jody Dushay, an endocrine specialist at Beth Israel Deaconess Medical Center. Weight loss typically begins right away and continues as the dosage increases. For some patients, that just doesn't happen. For others, side effects such as nausea, vomiting and diarrhea force them to halt the medications, Dushay said. In such situations, patients who were counting on the new drugs to pare pounds may think they’re out of options. “I tell them: It's not game over,” Dushay said. Trying a different version of the new class of drugs may help. Griffin, who didn't respond well to Wegovy, has started using Zepbound, which targets an additional hormone pathway in the body. After three months of using the drug, she has lost seven pounds. “I'm hoping it's slow and steady,” she said. Other people respond well to older drugs, the experts said. Changing diet, exercise, sleep and stress habits can also have profound effects. Figuring out what works typically requires a doctor trained to treat obesity, Saunders noted. “Obesity is such a complex disease that really needs to be treated very comprehensively,” she said. “If what we’re prescribing doesn’t work, we always have a backup plan.” The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.